← Compound index
COMPOUND RECORD / LANGOPEPT

LangopeptЛангопепт

An investigational peptide preparation derived from bronchial tissue. Russian trial registrations describe dose escalation in healthy volunteers and a Phase II study in chronic obstructive pulmonary disease. The registrations give study plans.

Source linked

What the studies found

Lab research · 2025

EDG at 1 ng/mL in rat lung, bronchial and arterial explants

Related laboratory finding · isolated EDG

Lung explant area index
+21 ± 3% versus controlDay 3p<0.05, Table 1
Bronchial explant area index
+3 ± 1% versus controlDay 3No significant difference reported, Table 2
Bronchial artery explant area index
+3 ± 1% versus controlDay 3No significant difference reported, Table 3

An experiment with isolated EDG at 1 ng/mL increased rat lung-explant area index by 21 ± 3%. Changes in bronchial and bronchial artery tissue were small and statistically inconclusive. The result applies to isolated EDG.

Study notes · methods, sources and limitations

Participants or model Three-month-old Wistar rats provided 230 lung, 200 bronchial and 210 bronchial artery explants across all experiments. Each dish contained 18–20 explants. The report does not give EDG-specific counts or the number of donor rats.

Design Organotypic tissue culture with phase-contrast microscopy. Investigators calculated total explant area relative to the central zone and set the control index to 100%.

Explants across all experiments
230 lung, 200 bronchial and 210 bronchial artery explants. Each dish contained 18–20 explants.The authors give no EDG-specific counts or total number of donor rats.

Important limitations

  • The area index measures laboratory explant growth. The authors do not give the EDG-specific group sizes or number of source animals. The exposure concerns EDG alone, so the findings apply to that peptide in this assay.

Integrative Physiology. 2025;6(3):329–337. · Publication record

Original source or citation ↗

Study results and tables ↗

Laboratory analysis · 2020

Identification of short peptides in the composition of polypeptide complexes isolated from animal organs

Findings for this preparation

EDG and AEDL in the bronchial mucosa complex
EDG 0.028% and AEDL 0.060% of the analyzed extract

UHPLC–MS detected 0.028% EDG and 0.060% AEDL in the bronchial mucosa extract. The analysis does not identify the clinical trial batch.

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency

Study notes · methods, sources and limitations

Participants or model Animal-organ polypeptide complexes analyzed by UHPLC–MS

Design UHPLC–tandem mass spectrometry of six lyophilized animal-tissue complexes, using reference standards for seven target sequences.

Important limitations

  • Molecular detection does not prove identical pharmacology or clinical equivalence. The paper’s discussion of clinical work is not an independent clinical trial.
  • These measurements describe the analyzed preparations. The paper does not characterize all constituents or identify the clinical trial batch.

Uspekhi Sovremennoi Biologii 140(2):140–148 · Publication record

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Langopept

Names in this research collection

Langopept COPD · LNG-11-2022 · LNG-04-2019

Identity / background source ↗

Research background

An investigational peptide mixture prepared from calf bronchial mucosa and formulated for intramuscular injection. Human trial registrations, a preclinical conference report, and laboratory findings on individual peptides are linked below.

More study findings

Planned study · 2023

Langopept Phase II placebo-controlled COPD trial registration

PeptidPRO’s double-blind COPD trial lists 200 planned participants. Clinomir marks the study completed. Actual enrollment, doses administered and results remain unavailable.

Study notes · methods, sources and limitations

Participants or model 200 planned participants with moderate-to-severe chronic obstructive pulmonary disease (COPD). Actual enrollment and arm sizes are unavailable.

Design Multicenter, double-blind, randomized, parallel-group placebo-controlled design. ClinLine lists investigators T. I. Ishina, V. V. Popov and N. D. Krasnopeeva.

Planned enrollment
200 participants

Important limitations

  • The registry target was 200. Clinomir gives an administrative completion status without participant flow, study endpoint data, or adverse-event tables.

Russian clinical-trial registry record, authorization 262, 5 May 2023. Protocol LNG-11-2022. · Trial registry reproduction

Original source or citation ↗

Study results and tables ↗

Planned study · 2019

Langopept Phase I dose-escalation registration

MedInvest’s Phase I record lists 42 planned healthy volunteers. Clinomir marks the study completed. Actual enrollment, dose steps and safety results remain unavailable.

Study notes · methods, sources and limitations

Participants or model 42 healthy adults planned at Kazan Federal University. The entry does not report actual enrollment or cohort sizes.

Design Randomized, double-blind, placebo-controlled, ascending-dose study at Kazan Federal University. The registry identifies G. M. Kamalov as investigator.

Planned enrollment
42 healthy volunteers

Important limitations

  • The registry lists a study design and formulation strength. It supplies no treatment outcomes or adverse-event counts.

Russian clinical-trial registry record, authorization 504, 6 September 2019. Protocol LNG-04-2019. · Trial registry reproduction

Original source or citation ↗

Study results and tables ↗

Research record · 2017

Langopept extract in an early preclinical conference report

Reported experimental findings for the extract
The authors describe changes in bronchial mucosal metabolism and repair of alveolar and bronchial epithelium.

The developers described effects on bronchial mucosal metabolism and on the repair of alveolar and bronchial epithelium in experimental models. The abstract gives no numerical outcomes.

Study notes · methods, sources and limitations

Participants or model The abstract refers to experimental models without giving a species, model protocol, or number per group for Langopept.

Design Conference summary from the St. Petersburg Institute of Bioregulation and Gerontology, describing several preparations in development.

Important limitations

  • The conference abstract does not identify the Langopept models, group sizes, comparators, endpoints, or effect sizes. It predates both trial registrations.

Uspekhi Gerontologii. 2017;30(6 Suppl):67. Innovative Russian Technologies in Gerontology and Geriatrics, St. Petersburg, 14–16 December 2017. · Conference abstract · preclinical program summary

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Research updates ↗

Compound class
Tissue-derived peptide preparation
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Phase I: 42 healthy volunteers planned. Phase II: 200 COPD patients planned.

Study methods

Double-blind placebo-controlled designs. Actual enrollment and dosing schedules are unavailable.

Independent replication

Comparative findings are unavailable in the linked records.

Source access

Russian registry entries for protocols LNG-04-2019 and LNG-11-2022.

Safety evidence

Phase I was designed to assess tolerability. Adverse-event results are unavailable.

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗
03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Planned study · 2023

Langopept Phase II placebo-controlled COPD trial registration

PeptidPRO’s double-blind COPD trial lists 200 planned participants. Clinomir marks the study completed. Actual enrollment, doses administered and results remain unavailable.

Study notes and original source
2023Trial protocol / registrationFull text available

Langopept Phase II placebo-controlled COPD trial registration

· Trial registry reproduction

PeptidPRO · Russian clinical-trial registry record, authorization 262, 5 May 2023. Protocol LNG-11-2022.

PeptidPRO’s double-blind COPD trial lists 200 planned participants. Clinomir marks the study completed. Actual enrollment, doses administered and results remain unavailable.

Results and tables

Reported findings and study design

The patent gives no measured outcomes

Multicenter, double-blind, randomized, parallel-group placebo-controlled design. ClinLine lists investigators T. I. Ishina, V. V. Popov and N. D. Krasnopeeva.

Dose, route and schedule

The registry lists a 5 mg lyophilized formulation for intramuscular injection and a placebo control. It does not give the per-visit dose, frequency or treatment duration.

Protocol source ↗ · ClinLine trial entry and Clinomir sponsor listing for PeptidPRO.

Results · ClinLine trial entry and Clinomir sponsor listing for PeptidPRO.
MeasureResultComparison, timing and statistics
Planned enrollment200 participants

Source for these results ↗ · Reviewed 2026-11-15

Population / setting
200 planned participants with moderate-to-severe chronic obstructive pulmonary disease (COPD). Actual enrollment and arm sizes are unavailable.
Source reviewed
ClinLine trial entry and Clinomir sponsor listing for PeptidPRO.
Study limitations
  • The registry target was 200. Clinomir gives an administrative completion status without participant flow, study endpoint data, or adverse-event tables.

Reviewed 2026-11-15.

Read the source ↗

Planned study · 2019

Langopept Phase I dose-escalation registration

MedInvest’s Phase I record lists 42 planned healthy volunteers. Clinomir marks the study completed. Actual enrollment, dose steps and safety results remain unavailable.

Study notes and original source
2019Trial protocol / registrationFull text available

Langopept Phase I dose-escalation registration

· Trial registry reproduction

MedInvest · Russian clinical-trial registry record, authorization 504, 6 September 2019. Protocol LNG-04-2019.

MedInvest’s Phase I record lists 42 planned healthy volunteers. Clinomir marks the study completed. Actual enrollment, dose steps and safety results remain unavailable.

Results and tables

Reported findings and study design

The patent gives no measured outcomes

Randomized, double-blind, placebo-controlled, ascending-dose study at Kazan Federal University. The registry identifies G. M. Kamalov as investigator.

Dose, route and schedule

Single and then repeated escalating intramuscular doses versus placebo. The registry lists a 5 mg vial. Dose levels, intervals and duration are unavailable.

Protocol source ↗ · ClinLine trial entry, MedInvest sponsor listing and Kazan Federal University investigator record.

Results · ClinLine trial entry, MedInvest sponsor listing and Kazan Federal University investigator record.
MeasureResultComparison, timing and statistics
Planned enrollment42 healthy volunteers

Source for these results ↗ · Reviewed 2026-11-15

Population / setting
42 healthy adults planned at Kazan Federal University. The entry does not report actual enrollment or cohort sizes.
Source reviewed
ClinLine trial entry, MedInvest sponsor listing and Kazan Federal University investigator record.
Study limitations
  • The registry lists a study design and formulation strength. It supplies no treatment outcomes or adverse-event counts.

Reviewed 2026-11-15.

Read the source ↗

Research record · 2017

Langopept extract in an early preclinical conference report

The developers described effects on bronchial mucosal metabolism and on the repair of alveolar and bronchial epithelium in experimental models. The abstract gives no numerical outcomes.

Study notes and original source
2017Study design unresolvedRussian-language source

Langopept extract in an early preclinical conference report

Polypeptide complex prepared from calf bronchial mucosa, named Langopept in the abstract. · Conference abstract · preclinical program summary

G. A. Ryzhak, V. N. Rutkovskaya, A. P. Ryzhak · Uspekhi Gerontologii. 2017;30(6 Suppl):67. Innovative Russian Technologies in Gerontology and Geriatrics, St. Petersburg, 14–16 December 2017.

The developers described effects on bronchial mucosal metabolism and on the repair of alveolar and bronchial epithelium in experimental models. The abstract gives no numerical outcomes.

Results and tables

Reported findings and study design

Findings described in words

Conference summary from the St. Petersburg Institute of Bioregulation and Gerontology, describing several preparations in development.

Population or model The abstract refers to experimental models without giving a species, model protocol, or number per group for Langopept.

Protocol information

The abstract gives no dose, route, or schedule for Langopept.

Protocol source ↗ · Russian abstract on printed page 67 of the journal supplement, recovered via the indexed copy. The meeting program confirms the presentation.

Results · Russian abstract on printed page 67 of the journal supplement, recovered via the indexed copy. The meeting program confirms the presentation.
MeasureResultComparison, timing and statistics
Reported experimental findings for the extractThe authors describe changes in bronchial mucosal metabolism and repair of alveolar and bronchial epithelium.

Source for these results ↗ · Reviewed 2026-11-15

Population / setting
The abstract refers to experimental models without giving a species, model protocol, or number per group for Langopept.
Source reviewed
Russian abstract on printed page 67 of the journal supplement, recovered via the indexed copy. The meeting program confirms the presentation.
Study limitations
  • The conference abstract does not identify the Langopept models, group sizes, comparators, endpoints, or effect sizes. It predates both trial registrations.

Reviewed 2026-11-15.

Read the source ↗

Lab research · 2025

EDG at 1 ng/mL in rat lung, bronchial and arterial explants

An experiment with isolated EDG at 1 ng/mL increased rat lung-explant area index by 21 ± 3%. Changes in bronchial and bronchial artery tissue were small and statistically inconclusive. The result applies to isolated EDG.

Study notes and original source
2025In vitroFull text available

EDG at 1 ng/mL in rat lung, bronchial and arterial explants

Defined Glu–Asp–Gly (EDG, Chonluten), a sequence detected in the bronchial extract. The experiment used the individual peptide.

N. I. Chalisova, P. N. Ivanova, E. S. Egozova, E. A. Nikitina · Integrative Physiology. 2025;6(3):329–337.

At 1 ng/mL, EDG increased the lung explant area index by 21 ± 3% versus control. The index rose by 3 ± 1% in bronchial and bronchial artery cultures, with neither change statistically significant.

Results and tables

Reported findings and study design

Organotypic tissue culture with phase-contrast microscopy. Investigators calculated total explant area relative to the central zone and set the control index to 100%.

Dose, route and schedule

EDG at 1 ng/mL in 3 mL of culture medium for three days at 37 °C. Control dishes received the same medium without added peptide.

Protocol source ↗ · Original article, culture methods, explant counts and Tables 1–3. Results here concern the EDG arm.

Results · Original article, culture methods, explant counts and Tables 1–3. Results here concern the EDG arm.
MeasureResultComparison, timing and statistics
Lung explant area index+21 ± 3% versus controlDay 3 · p<0.05, Table 1
Bronchial explant area index+3 ± 1% versus controlDay 3 · No significant difference reported, Table 2
Bronchial artery explant area index+3 ± 1% versus controlDay 3 · No significant difference reported, Table 3
Explants across all experiments230 lung, 200 bronchial and 210 bronchial artery explants. Each dish contained 18–20 explants.The authors give no EDG-specific counts or total number of donor rats.

Source for these results ↗ · Reviewed 2026-11-15

Population / setting
Three-month-old Wistar rats provided 230 lung, 200 bronchial and 210 bronchial artery explants across all experiments. Each dish contained 18–20 explants. The report does not give EDG-specific counts or the number of donor rats.
Source reviewed
Original article, culture methods, explant counts and Tables 1–3. Results here concern the EDG arm.
Study limitations
  • The area index measures laboratory explant growth. The authors do not give the EDG-specific group sizes or number of source animals. The exposure concerns EDG alone, so the findings apply to that peptide in this assay.

Reviewed 2026-11-15.

Read the source ↗

Laboratory analysis · 2020

Identification of short peptides in the composition of polypeptide complexes isolated from animal organs

UHPLC–MS detected 0.028% EDG and 0.060% AEDL in the bronchial mucosa extract. The analysis does not identify the clinical trial batch.

Study notes and original source
2020Analytical / composition studyFull text available

Identification of short peptides in the composition of polypeptide complexes isolated from animal organs

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology · Pavlov Institute of Physiology, Russian Academy of Sciences · Institute of Toxicology, Federal Medical-Biological Agency

I. K. Zhurkovich, N. G. Kovrov, G. A. Ryzhak, E. S. Mironova, V. Kh. Khavinson · Uspekhi Sovremennoi Biologii 140(2):140–148

Reports KED in vessel complex, AED in cartilage, EDG and AEDL in bronchial mucosa, EDR in brain and KEDW in pancreas. This strengthens sequence-level links in the research program.

Results and tables

Reported findings and study design

UHPLC–tandem mass spectrometry of six lyophilized animal-tissue complexes, using reference standards for seven target sequences.

Population or model Animal-organ polypeptide complexes analyzed by UHPLC–MS

Results · Original analytical paper, Table 3 and chromatograms.
MeasureResultComparison, timing and statistics
EDG and AEDL in the bronchial mucosa complexEDG 0.028% and AEDL 0.060% of the analyzed extract
Identified short peptides by extract
Identified short peptides by extract
ExtractSequenceReported proportion
Bronchial mucosaEDG0.028%
Bronchial mucosaAEDL0.060%
VesselsKED0.020%
CartilageAED0.020%
BrainEDR0.024%
PancreasKEDW0.035%

These measurements describe the analyzed preparations. The paper does not characterize all constituents or identify the clinical trial batch.

Source for these results ↗ · Reviewed 2026-11-15

Population / setting
Animal-organ polypeptide complexes analyzed by UHPLC–MS
Source reviewed
Original analytical paper, test method, Table 3 and chromatograms in Figures 1–6.
Study limitations
  • Molecular detection does not prove identical pharmacology or clinical equivalence.
  • The paper’s discussion of clinical work is not an independent clinical trial.

Reviewed 2026-11-15.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗